Skip to main content

Table 5 Hazard ratios for all-cause mortality during the 3-year follow-up after treatment initiationa, mRCC patients, Estonia 2004–2012

From: Changes in therapy and survival of metastatic renal cell carcinoma in Estonia

 Crude HR95% CIAdjustedb HR95% CIAdjustedb HR95% CI
Treatment group
 Group 2c1.00 1.00 1.00 
 Group 1d2.291.79–2.922.151.65–2.793.882.64–5.72
Age group
 15–591.00 1.00 1.00 
 60–690.830.63–1.110.890.67–1.190.850.64–1.14
 70+0.940.71–1.260.960.71–1.280.870.64–1.17
Sex
 Male1.00 1.00 1.00 
 Female0.730.57–0.940.700.54–0.910.710.55–0.93
Histology
 Clear Cell1.00 1.00 1.00 
 Non clear cell2.001.49–2.691.360.99–1.871.481.07–2.04
Nephrectomy
 Done1.00 1.00 1.00 
 Not done1.901.41–2.571.621.19–2.211.531.12–2.09
Treatment period
 2004–20071.00  1.00 
 2008–20120.810.63–1.03 2.221.52–3.24
  1. a patients with unknown histology (n = 6) and other surgery (n = 5) excluded
  2. b adjusted for all variables in the table
  3. c treatment with INFa followed by targeted agents or targeted agents only
  4. dtreatment with INFa only